SS-31: A promising therapeutic agent against bleomycin-induced pulmonary fibrosis in Mice
Related Experiment Video
Updated: May 9, 2025
A Mouse Model of Pulmonary Fibrosis Induced by Nasal Bleomycin Nebulization
Published on: January 20, 2023
Quankuan Gu1,2, Yunlong Wang1,2, Haichao Zhang1,2
1Department of Critical Care Medicine, the First Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang Province, China.
Objective:
The aim of this research was to investigate if the mitochondria- targeting peptide SS-31 could serve as a protective measure against bleomycin-induced pulmonary fibrosis in mice.
Method:
Mice were split into four groups named CON group, SS-31 group, BLM group, and the BLM + SS-31 group. SS-31 (intraperitoneal injection, 5mg/Kg) was administered daily from the day prior to the experiment for the control and model groups. Mice were euthanized after 28 days of the experiment, following which blood, bronchoalveolar lavage fluid, and lung tissue were collected for analysis.
Results:
BLM caused a large decrease in body weight in mice. However, the intraperitoneal injection of SS-31 slowed down the body weight loss in the mice. It was observed through HE and Masson staining, immunohistochemistry, hydroxyproline detection, and fibrosis index measurement via Western blot that SS-31 could alleviate pulmonary fibrosis caused by BLM. Electron microscopy and ATP detection further suggested that SS-31 might help protect mitochondrial structure and function. It was also found that SS-31 could reduce reactive oxygen species and myeloperoxidase, thereby alleviating the reduction of antioxidant factor MPO and SOD, as well as diminishing the inflammatory factors TNF-α, IL-1 β, and IL-6.
Conclusion:
The mitochondria-targeting drug SS-31 exhibited potential in mitigating bleomycin-induced pulmonary fibrosis, improving mitochondrial structural and functional damage, stabilizing the balance between oxidative and antioxidant systems, reducing inflammatory factor expression, and improving apoptosis in lung tissue.
Insights
The mitochondria-targeting peptide SS-31 shows promise in protecting against bleomycin-induced pulmonary fibrosis. This peptide helps mitigate lung damage by improving mitochondrial function and reducing inflammation.
Area of Science:
- Mitochondrial Medicine
- Pulmonary Fibrosis Research
- Pharmacology
Background:
- Pulmonary fibrosis is a debilitating lung disease with limited treatment options.
- Bleomycin (BLM) is a chemotherapeutic agent that induces pulmonary fibrosis in preclinical models.
- Mitochondrial dysfunction plays a critical role in the pathogenesis of pulmonary fibrosis.
Purpose of the Study:
- To investigate the therapeutic potential of the mitochondria-targeting peptide SS-31 against bleomycin-induced pulmonary fibrosis.
- To evaluate the effects of SS-31 on mitochondrial structure and function in a mouse model of pulmonary fibrosis.
Main Methods:
- Mice were administered bleomycin (BLM) to induce pulmonary fibrosis.
- Mice received daily intraperitoneal injections of SS-31.
- Lung tissue, bronchoalveolar lavage fluid, and blood were collected for histological, biochemical, and molecular analyses.
Main Results:
- SS-31 administration significantly attenuated BLM-induced body weight loss and pulmonary fibrosis.
- SS-31 improved mitochondrial structure and function, evidenced by ATP levels and electron microscopy.
- SS-31 reduced oxidative stress, inflammation (TNF-α, IL-1β, IL-6), and apoptosis in lung tissue.
Conclusions:
- Mitochondria-targeting peptide SS-31 demonstrates significant protective effects against bleomycin-induced pulmonary fibrosis.
- SS-31 ameliorates pulmonary fibrosis by enhancing mitochondrial integrity, balancing oxidative stress, and suppressing inflammation.
- SS-31 holds potential as a novel therapeutic agent for pulmonary fibrosis.
More Related Videos
06:52Induction of Mouse Lung Injury by Endotracheal Injection of Bleomycin
Published on: April 30, 2019
07:38A Multimodal Imaging Approach Based on Micro-CT and Fluorescence Molecular Tomography for Longitudinal Assessment of Bleomycin-Induced Lung Fibrosis in Mice
Published on: April 13, 2018